Amgen

Amgen Inc. (Nasdaq: AMGN) is a prominent American multinational biotechnology firm established in 1980. Headquartered in Thousand Oaks, California, the company specializes in the development of human therapeutics, focusing on complex areas such as oncology, hematology, cardiovascular disease, and bone health. As a pioneer in the biopharmaceutical sector, Amgen utilizes advanced scientific innovation to address serious medical conditions through precision medicine and large-scale manufacturing processes.

The organization maintains a robust operational footprint with over 40 global locations and a workforce exceeding 10,000 employees. Learn about Amgen's global headquarters for detailed geographic insights into their infrastructure. Amgen’s technical capabilities span the entire drug development lifecycle, from investigative research to the delivery of specialized medications like Neulasta. Their commitment to scientific rigor is supported by extensive R&D investments and a diverse portfolio of therapeutic candidates designed to improve patient outcomes across various chronic diseases.

Financially, Amgen demonstrates significant market strength, reporting annual revenue of $38.1B. Explore financial highlights to review their fiscal performance and funding history, including recent debt financing initiatives. The company operates within a competitive landscape alongside major pharmaceutical entities like Roche, Merck, and Pfizer. Meet Amgen's team to understand the leadership driving their strategic initiatives and organizational structure. By leveraging a sophisticated B2B and B2C model, Amgen continues to advance its position as a leader in the global biotechnology industry.